Daniel Joseph Dorgan, MD
Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)
Associate Program Director, Adult Cystic Fibrosis Program, University of Pennsylvania
Program Director, Adult Primary Ciliary Dyskinesia Program, University of Pennsylvania
Site Director, Therapeutics Development Network (Site Principal Investigator), Adult Cystic Fibrosis Program, University of Pennsylvania
Medical Director, Pulmonary Diagnostic Services, Perelman Center for Advanced Medicine, University of Pennsylvania Health System
Director, Advanced Lung Disease Clinical Research Group, University of Pennsylvania
Vice Chief of Clinical Affairs, Division of Pulmonary, Allergy, and Critical Care Medicine
University of Pennsylvania
Department: Medicine
Contact information
Harron Lung Center
3400 Civic Center Blvd
Philadelphia, PA 19104
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-3202
Fax: 215-349-8432
Fax: 215-349-8432
Education:
BS (Biochemistry)
Michigan State University, 1998.
MD
University of Michigan, 2004.
Permanent linkBS (Biochemistry)
Michigan State University, 1998.
MD
University of Michigan, 2004.
Description of Clinical Expertise
Cystic FibrosisBronchiectasis
Ciliary Dyskinesia
Pulmonary Mycobacterial Infections
Chronic Pulmonary Infections
Description of Research Expertise
Cystic FibrosisBronchiectasis
Ciliary Dyskinesia
Pulmonary Mycobacterial Infections
Selected Publications
Lee IK, Jacome DA, Cho JK, Tu V, Young AJ, Dominguez T, Northrup JD, Etersque JM, Lee HS, Ruff A, Aklilu O, Bittinger K, Glaser LJ, Dorgan D, Hadjiliadis D, Kohli RM, Mach RH, Mankoff DA, Doot RK, Sellmyer MA: Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. The Journal of Clinical Investigation 132(18): e156679, Sep 2022.Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group: Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine 205(5): 529-539, Mar 2022.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O’Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, on behalf of the SIMPLIFY Study Group: Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. The Lancet Respiratory Medicine 2022 Notes: Online first, DOI:https://doi.org/10.1016/S2213-2600(22)00434-9.
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators: A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine 65(1): 1295-1305, Dec 2021.
Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA: Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation. Journal of Cystic Fibrosis 20(2): 288-294, Mar 2021.
Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan D, Kohanski MA, Palmer JN, Adappa ND: Impact of Novel CFTR Modulator on Sinonasal Quality of Life in Adult Patients with Cystic Fibrosis. International Forum of Allergy & Rhinology 11(2): 201-203, Feb 2021.
Rowe SW, Dorgan D, Lascano J, Zuckerman JB, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar VM, Lechtzin N, McBennet K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Meltzer EB, Barbier AJ: Safety and tolerability of Single and Repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients. North American Cystic Fibrosis Conference, San Antonio, TX 2021 Notes: poster presentation.
Hong G, Daniel SG, Lipscombe C, Bittinger K, O’Dea A, Dorgan DJ, Hadjiliadis D: The impact of highly-effective CFTR modulation on the microbial environment in cystic fibrosis. North American Cystic Fibrosis Conference, San Antonio, TX 2021 Notes: poster presentation.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, and Daley CL for the WILLOW Investigators: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine 383(22): 2127-2137, Nov 2020.
Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, Kreider M: A phase II clinical trial of the Safety of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. Respiratory Medicine 163: 105898 (ePub), Feb 2020.